• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

    12/30/25 6:00:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email

    The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.

    [LEARN MORE ABOUT THE INVESTIGATION]

    What Happened?

    On July 30, 2025, Anika issued a press release announcing topline results from its clinical trial of Hyalofast, "a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis." On this news, the price of Anika shares declined by $3.06 per share, or approximately 27.42%, to close at $8.10 per share on July 30, 2025.

    What Should I Do?

    If you purchased or otherwise acquired Anika securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

    [LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

    Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.

    This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251230549121/en/

    Kirby McInerney LLP

    Lauren Molinaro, Esq.

    212-699-1171

    https://www.kmllp.com

    https://securitiesleadplaintiff.com/

    investigations@kmllp.com

    Get the next $ANIK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mcleod Ian

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/23/26 5:23:05 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    EVP, General Counsel, Corp Sec Colleran David converted options into 15,837 shares, was granted 4,694 shares and covered exercise/tax liability with 6,061 shares, increasing direct ownership by 27% to 67,570 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/17/26 7:47:22 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    President and CEO Griffin Stephen D. was granted 6,412 shares, covered exercise/tax liability with 5,944 shares and converted options into 12,824 shares, increasing direct ownership by 125% to 23,963 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    3/17/26 7:44:08 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/26/26 3:45:54 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

    2/26/26 7:18:31 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

    1/8/26 4:02:04 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics upgraded by Barrington Research with a new price target

    Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

    8/14/23 9:16:10 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units ("RSUs") covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made a

    4/3/26 5:00:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Fourth Quarter and Full Year 2025 Financial Results

    Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3

    2/26/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference

    BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a on

    2/18/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    View All

    Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

    NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat

    2/4/26 8:54:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Announces Leadership Transition

    Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griff

    1/8/26 7:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

    SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/8/24 2:17:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    5/30/24 4:31:25 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/6/24 7:30:09 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Financials

    Live finance-specific insights

    View All

    Anika Reports Fourth Quarter and Full Year 2025 Financial Results

    Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3

    2/26/26 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's

    2/12/26 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care